The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta ‐analysis

ConclusionsAtrial fibrillation incidence in breast cancer patients receiving trastuzumab was around 1.2%. It was not influenced by the formulation of trastuzumab, the additional use of neoplastic agents, anthracycline exposure status, or concurrent radiotherapy.

Source: Cardiovascular Therapeutics - November 28, 2018 Category: Cardiology Authors: Ming Yuan, Gary Tse, Zhiwei Zhang, Xu Han, William K. K. Wu, Guangping Li, Yunlong Xia, Tong Liu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research